熱門資訊> 正文
FDA重新考虑湿AMD疗法审查前景增强
2026-06-16 21:23
- Outlook Therapeutics (OTLK) traded higher in the premarket on Tuesday after the U.S. Food and Drug Administration agreed to reconsider its marketing application for ONS-5010, a treatment targeting the eye disorder wet age-related macular degeneration (wet AMD).
- The company shares crashed earlier this year after the FDA issued a complete response letter, declining to approve ONS-5010, which the regulator had already rejected in August.
- Also known as Lytenava, ONS-5010 is an ophthalmic formulation of bevacizumab, a biologic therapy marketed by Roche (RHHBY) as Avastin.
- Earlier this month, the New Jersey-based biotech said it has resubmitted a Biologics License Application for ONS-5010 for neovascular age-related macular degeneration (nAMD) or wet AMD. The FDA has issued a Class 1 review and a target action date of July 29, 2026, in connection with the BLA.
More on Outlook Therapeutics
- Outlook Therapeutics: Potential Catalysts Offering An Arbitrage Opportunity
- Outlook Therapeutics prices $5M registered direct offering
- Outlook Therapeutics announces $5M registered direct offering priced at-the-market
- Seeking Alpha’s Quant Rating on Outlook Therapeutics
- Historical earnings data for Outlook Therapeutics
推薦文章
乾貨集錦！《跑贏美股》6月直播核心觀點總結
美股前瞻 | AI牛市不停！美光績后狂飆17%帶飛存儲板塊；美國5月核心PCE同比增3.4%；IBM推出全球首款小於1nm芯片
壓力測試過關 摩根大通、高盛等美國大型銀行提高股利並回購股份
華盛早報 | 美光盤后飆升近16%！炸裂財報引爆芯片股，納指期貨應聲漲2%；黃仁勛豪言AI進入盈利時代；高通全面進軍AI數據中心
港股概念追蹤 | 曝蘋果摺疊屏iPhone敲定7月底量產 產業鏈有望迎來高速發展拐點(附概念股)
美股前瞻 | AI風向標來襲！英偉達股東大會凌晨開始、美光財報盤后發佈；布油跌破75美元創戰后新低；海力士或7月10日登陸美股
拋售SpaceX，買入特斯拉？
資金覆盤 | 北水逆勢抄底港股近104億港元！加倉中芯國際、建滔集團，拋售阿里巴巴
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
